Light-activated carriers for the controlled delivery of therapeutic peptides in posterior segment eye diseases

Project description

Light-activated nanocarriers for drug release in the eye

Macular degeneration and glaucoma are age-related eye diseases which are expected to increase in prevalence due to the rise in the ageing population. Since these diseases impair vision and hence quality of life, there is a need for efficient administration of therapeutics. The key objective of the EU-funded Light4Sight project is to develop a nanotechnology-based drug delivery system that contains therapeutic peptides within a light-sensitive hydrogel. The hydrogel can be injected in the vitreous, the clear gel that fills the space between the lens and the retina. Drug release will be activated by visible light in a controlled manner, avoiding toxicity while increasing the half-life of the therapeutic.

Fields of science

• medical and health sciences › clinical medicine › ophthalmology › glaucoma
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › clinical medicine › ophthalmology › retinopathy

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

QUEEN MARY UNIVERSITY OF LONDON

Net EU contribution

€ 224 933,76

Address

327 Mile End Road
E1 4NS London
United Kingdom

Region

London › Inner London — East › Tower Hamlets

Activity type

Higher or Secondary Education Establishments

Links

Other funding

€ 0,00